PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation

GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit

Sander Pronk, Szilárd Páll, Roland Schulz et al. · Bioinformatics · 2013 · 7.6K citations · Full text

Natural Sciences, Chemistry, High-performance Computing +17

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Stephen G. O’Brien, François Guilhot, Richard A. Larson et al. · New England Journal of Medicine · 2003 · 3.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Medicine, Hematology, Oncology +13

ACPYPE - AnteChamber PYthon Parser interfacE

Alan Sousa da Silva, Wim Vranken · BMC Research Notes · 2012 · 3.1K citations · Full text

Life Sciences, Bioinformatics, Chemistry +16

Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

Neil P. Shah, Chris Tran, Francis Y. Lee et al. · Science · 2004 · 1.8K citations

Medicine, Oncology, Pharmacology +14